51. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer
- Author
-
Houlahan, Kathleen E, Salmasi, Amirali, Sadun, Taylor Y, Pooli, Aydin, Felker, Ely R, Livingstone, Julie, Huang, Vincent, Raman, Steven S, Ahuja, Preeti, Sisk, Anthony E, Boutros, Paul C, and Reiter, Robert E
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Prostate Cancer ,Aging ,Urologic Diseases ,Cancer ,Biomedical Imaging ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Aged ,Gene Dosage ,Gene Expression Profiling ,Genome ,Humans ,Male ,Middle Aged ,Multiparametric Magnetic Resonance Imaging ,Prostatic Neoplasms ,RNA ,Long Noncoding ,RNA ,Messenger ,RNA ,Small Nuclear ,Transcriptome ,Tumor Burden ,Tumor Microenvironment ,Prostate cancer ,Multiparametric magnetic resonance imaging visibility ,Radiogenomics ,Nimbosus ,Transcriptomics ,Urology & Nephrology ,Clinical sciences - Abstract
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2
- Published
- 2019